mycophenolate sandoz mycophenolate mofetil 250mg capsule blister pack
sandoz pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: magnesium stearate; pregelatinised maize starch; titanium dioxide; povidone; croscarmellose sodium; gelatin; indigo carmine; iron oxide red; iron oxide yellow - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.
mycophenolate sandoz mycophenolate mofetil 500mg tablet blister pack
sandoz pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; hypromellose; povidone; purified talc; titanium dioxide; croscarmellose sodium; macrogol 400; iron oxide red; iron oxide black; microcrystalline cellulose; magnesium stearate - mycophenolate sandoz is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. . mycophenolate sandoz is indicated for the prophylaxis of organ rejection in paediatric patients (6 to 18 years) receiving allogeneic renal transplants.
mycophenolate an mycophenolate mofetil 500mg tablet blister pack
amneal pharma australia pty ltd - mycophenolate mofetil -
pc-mycophenolate 500 mycophenolate mofetil 500mg tablet blister pack
pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.
pharmacor mycophenolate 250 mycophenolate mofetil 250 mg capsule blister pack
pharmacor pty ltd - mycophenolate mofetil, quantity: 250 mg - capsule - excipient ingredients: pregelatinised maize starch; povidone; croscarmellose sodium; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; titanium dioxide; indigo carmine; iron oxide yellow; iron oxide red; gelatin; sodium lauryl sulfate - pharmacor mycophenolate 250 is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. pharmacor mycophenolate 250 is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.
mycophenolate mofetil- mycophenolate mofetil tablet
american health packaging - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 500 mg - mycophenolate mofetil tablet, usp is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. mycophenolate mofetil tablets, usp should be used concomitantly with cyclosporine and corticosteroids. mycophenolate mofetil intravenous is an alternative dosage form to mycophenolate mofetil capsules, tablets and oral suspension. mycophenolate mofetil intravenous should be administered within 24 hours following transplantation. mycophenolate mofetil intravenous can be administered for up to 14 days; patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. mycophenolate mofetil intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).
mycophenolate mofetil- mycophenolate mofetil capsule
american health packaging - mycophenolate mofetil (unii: 9242ecw6r0) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolate mofetil 250 mg - mycophenolate mofetil capsule, usp is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. mycophenolate mofetil capsules, usp should be used concomitantly with cyclosporine and corticosteroids. mycophenolate mofetil intravenous is an alternative dosage form to mycophenolate mofetil capsules, tablets and oral suspension. mycophenolate mofetil intravenous should be administered within 24 hours following transplantation. mycophenolate mofetil intravenous can be administered for up to 14 days; patients should be switched to oral mycophenolate mofetil as soon as they can tolerate oral medication. allergic reactions to mycophenolate mofetil have been observed; therefore, mycophenolate mofetil is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. mycophenolate mofetil intravenous is contraindicated in patients who are allergic to polysorbate 80 (tween).
pharmacor mycophenolate 500 mycophenolate mofetil 500mg tablet blister pack
pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; hyprolose; purified talc; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.
mycophenolate gh mycophenolate mofetil 500 mg tablet blister pack
accord healthcare pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; hyprolose; povidone; purified talc; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; iron oxide black; macrogol 400; indigo carmine aluminium lake - prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. prophylaxis of organ rejection in paediatric patients (with a body surface area > 1.5 m2) receiving allogeneic renal transplants.
pharmacor mycophenolate 500 mycophenolate mofetil 500 mg film coated tablet blister
pharmacor pty ltd - mycophenolate mofetil, quantity: 500 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; macrogol 6000; iron oxide red; iron oxide black; macrogol 400 - mycophenolate mofetil is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants.,mycophenolate mofetil is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.